Cipla saw the highest growth of 249% in patent filings in October and 99% in grants in December in Q4 2023. Compared to Q3 2023, Q4 2023 saw an increase in patent filings by 249% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Cipla‘s patent filings and grants. Buy the databook here.
Cipla has been focused on protecting inventions in European Patent Office(EPO) with three publications in Q4 2023
The European Patent Office(EPO) Patent Office dominates the patent filings and grants with nearly 38% filings and 0% grants. The European Patent Office(EPO), United States(US), China(CN), and Australia(AU) patent Office are among the top ten patent offices where Cipla is filings its patents. Among the top granted patent authorities, Cipla has 50% of its grants in Australia(AU) and 50% in South Africa(ZA).
Johnson & Johnson could be the strongest competitor for Cipla
Patents related to rare diseases lead Cipla's portfolio
Cipla has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and no patents were granted in Q4 2023.
Schizophrenia related patents lead Cipla portfolio followed by chronic lymphocytic leukemia (cll), and lymphoma
Cipla has highest number of patents in schizophrenia followed by chronic lymphocytic leukemia (cll), lymphoma, mantle cell lymphoma, and waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma).
For comprehensive analysis of Cipla's filings and grants, buy the databook here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.